rTFPIRecombinant Tissue Factor Pathway Inhibitor
References in periodicals archive ?
published results from a prospective, randomized, placebo-controlled, and multinational phase II clinical trial assessing the safety of recombinant (r)TFPI administration, which indicated that treatment of sepsis patients with rTFPI reduced 28-day all-cause mortality compared to controls (45).
40) immuno- growth of human conjugates melanoma in a mouse xenograft model (in vivo) rTFPI TF Reduced Zoldhelyi et al.